Mitchell, Kyle G.
Amini, Behrang
Wang, Yunfei
Carter, Brett W.
Godoy, Myrna C. B.
Parra, Edwin R.
Behrens, Carmen
Villalobos, Pamela
Reuben, Alexandre
Lee, J. Jack
Weissferdt, Annikka
Moran, Cesar A.
Fujimoto, Junya
Sepesi, Boris
Walsh, Garrett L.
Vaporciyan, Ara A.
Hofstetter, Wayne L.
William, William N. Jr.
Gibbons, Don L.
Wang, Jing
Hwu, Patrick
Swisher, Stephen G.
Piwnica-Worms, David
Kadara, Humam
Wistuba, Ignacio I.
Heymach, John V.
Peng, Weiyi
Cascone, Tina
Funding for this research was provided by:
Conquer Cancer Foundation (12895)
Lung SPORE (5 P50 CA070907)
DoD PROSPECT Grant (W81XWH-07-1-0306)
CG Johnson Foundation Advanced Scholar Program Funds
University of Texas MD Anderson Physician Scientist Program and Lung Cancer Moon Shots Program
Bob Mayberry Foundation
Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Scholar Award)
MD Anderson Cancer Center Support Grant (P30CA01667)
Bruton Endowed Chair in Tumor Biology
National Cancer Institute (R01 CA187076, R01 CA184845)
T.J. Martell Foundation (US) Physician Scientist Program
Melanoma SPORE Grant (P50 CA221703)
Cancer Prevention and Research Institute of Texa (RP170401)
Article History
Received: 26 September 2019
Accepted: 31 March 2020
First Online: 16 April 2020
Compliance with ethical standards
:
: M.C.B. Godoy has received research funding from Siemens Healthcare. W.N. William has received honoraria/speaker’s fees and/or participated in advisory boards from Roche/Genentech, Bristol-Myers Squibb, Eli Lilly, Merck, AstraZeneca, and Pfizer. D.L. Gibbons has received research funding from AstraZeneca, Janssen, and Takeda and has participated in advisory boards for AstraZeneca and Sanofi. P. Hwu is a consultant and/or has participated in advisory boards for Immatics, Dragonfly, Sanofi, and GlaxoSmithKline. S.G. Swisher has participated in advisory committees for Ethicon and for the Peter MacCallum Cancer Center. B.S. receives consulting fees from Bristol-Myers Squibb. J.V. Heymach has received research support from AstraZeneca, Bayer, GlaxoSmithKline, and Spectrum; participated in advisory committees for AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GlaxoSmithKline, Guardant Health, Hengrui, Lilly, Novartis, Specrtum, EMD Serono, and Synta; and received royalties and/or licensing fees from Spectrum. P. Hwu and W. Peng have received research funding in the form of grants to MD Anderson Cancer Center from GlaxoSmith Kline. T. Cascone has received speaker’s fees from the Society for Immunotherapy of Cancer and Bristol-Myers Squibb; receives consulting/advisory role fees from MedImmune, Bristol-Myers Squibb and EMD Serono, and research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune and Bristol-Myers Squibb. No potential conflicts of interest are disclosed by the other authors.
: The study was approved by The University of Texas MD Anderson Cancer Center's Institutional Review Board (PROSPECT—LAB07-0233).
: All human studies were conducted in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all study participants.